[Lu-177]-PNT2002

DRUG2 trials

Sponsors

POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company, Lantheus Medical Imaging

Conditions

Castration-Resistant Prostatic CancerMetastatic Castration-Resistant Prostate Cancer

Phase 3

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

Active, not recruitingNCT04647526

POINT Biopharma, a wholly owned subsidiary of Eli Lilly and CompanyMetastatic Castration-Resistant Prostate Cancer

Start: 2021-02-25End: 2028-03-31Updated: 2026-01-13

Unknown Phase

Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Lantheus Medical ImagingCastration-Resistant Prostatic Cancer

Updated: 2025-01-13

Related Papers

Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial

Frontiers in Oncology2025-01-075 citations

Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies

EJNMMI Radiopharmacy and Chemistry2024-02-2611 citations

Nearly double the patients and dramatic changes over 14 years of UK MRT: Internal Dosimetry Users Group survey results from 2007 to 2021

Nuclear Medicine Communications2023-10-304 citations

Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using <sup>177</sup>Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH).

Journal of Clinical Oncology2021-05-2019 citations

Abstract PO-077: Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using 177Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH) - Trial in progress

Clinical Cancer Research2021-04-133 citations